Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
Cytek Biosciences, Inc. (CTKB)
Company Research
Source: Yahoo! Finance
FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025. “Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025 and reflects a continuation of positive trends we saw emerging in the third quarter. These trends include a continuation of strong growth in Services, Reagents and Asia Pacific instrument revenue and an improvement in instrument revenue growth in the US and EMEA . We were particularly pleased to see a return to positive grow
Show less
Read more
Impact Snapshot
Event Time:
CTKB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTKB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTKB alerts
High impacting Cytek Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CTKB
News
- Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue ResultsGlobeNewswire
- Cytek Biosciences (NASDAQ:CTKB) had its price target raised by analysts at TD Cowen from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Cytek Biosciences (NASDAQ:CTKB) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Cytek Biosciences (NASDAQ:CTKB) was given a new $6.00 price target on by analysts at Morgan Stanley.MarketBeat
- Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth [Seeking Alpha]Seeking Alpha
CTKB
Earnings
- 11/5/25 - Beat
CTKB
Sec Filings
- 1/13/26 - Form 8-K
- 11/20/25 - Form 4
- 11/20/25 - Form 4
- CTKB's page on the SEC website